Search alternatives:
point decrease » point increase (Expand Search)
mean decrease » a decrease (Expand Search)
nn decrease » _ decrease (Expand Search), a decrease (Expand Search), gy decreased (Expand Search)
we decrease » _ decrease (Expand Search), a decrease (Expand Search), teer decrease (Expand Search)
e point » _ point (Expand Search), 5 point (Expand Search), a point (Expand Search)
Showing 341 - 360 results of 39,647 for search '(( 5 ((((nn decrease) OR (we decrease))) OR (mean decrease)) ) OR ( e point decrease ))', query time: 0.65s Refine Results
  1. 341
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  2. 342
    Antibody and antigen responses to Ensovibep vs placebo day 1–90.

    Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  3. 343
    Long-term anti-nucleocapsid response by baseline patient characteristics.

    Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  4. 344
    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity.

    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  5. 345
    Baseline patient characteristics across neutralizing monoclonal antibody trials.

    Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  6. 346
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  7. 347
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  8. 348
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  9. 349
    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies.

    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  10. 350
    Study Flow Diagram.

    Study Flow Diagram. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  11. 351
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  12. 352
    Means ratings for FFM traits at each age interval for the self and others with post hoc analyses for mean differences.

    Means ratings for FFM traits at each age interval for the self and others with post hoc analyses for mean differences. by Joanna Gutral (12101779)

    Published 2022
    Save to List
    Saved in:
  13. 353
    Distribution of mean seasonal rainfall in the study area.

    Distribution of mean seasonal rainfall in the study area. by Menbere Sahilu (18195856)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  14. 354
    Distribution of mean monthly rainfall in the study area.

    Distribution of mean monthly rainfall in the study area. by Menbere Sahilu (18195856)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  15. 355
    Percentage decrease in model output peak with the administration of exogenous estrogen/progesterone.

    Percentage decrease in model output peak with the administration of exogenous estrogen/progesterone. by Brenda Lyn A. Gavina (15285185)

    Published 2023
    Save to List
    Saved in:
  16. 356
    Descriptive statistics of data presented in Tables 2–5.

    Descriptive statistics of data presented in Tables 2–5. by Héctor Raúl Olivares-Sánchez (13014866)

    Published 2022
    Save to List
    Saved in:
  17. 357
    RNF5 loss decreases PEL xenograft tumor growth and cell cycle gene expression.

    RNF5 loss decreases PEL xenograft tumor growth and cell cycle gene expression. by Xiaojuan Li (351842)

    Published 2023
    Save to List
    Saved in:
  18. 358
    The shortened version of the Edinburgh Handedness Inventory encompasses 4 items (e.g. writing) scored on a 5-point scale ranging from:” Always right; usually right; both equally; usually left; always left”.

    The shortened version of the Edinburgh Handedness Inventory encompasses 4 items (e.g. writing) scored on a 5-point scale ranging from:” Always right; usually right; both equally; u... by Marcel F. Hinss (14675457)

    Published 2024
    Save to List
    Saved in:
  19. 359
    Complete ELICIT TAC data.

    Complete ELICIT TAC data. by Godfrey Guga (12152390)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  20. 360
    ELICIT TAC data dictionary.

    ELICIT TAC data dictionary. by Godfrey Guga (12152390)

    Published 2023
    Subjects:
    Save to List
    Saved in:

Search Tools: